220 related articles for article (PubMed ID: 28641031)
21. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
Drenth JPH; Schattenberg JM
Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035
[TBL] [Abstract][Full Text] [Related]
22. New drugs for NAFLD: lessons from basic models to the clinic.
Reimer KC; Wree A; Roderburg C; Tacke F
Hepatol Int; 2020 Jan; 14(1):8-23. PubMed ID: 31802390
[TBL] [Abstract][Full Text] [Related]
23. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis.
Iwaki M; Yoneda M; Wada N; Otani T; Kobayashi T; Nogami A; Saito S; Nakajima A
Expert Opin Emerg Drugs; 2024 Jun; 29(2):127-137. PubMed ID: 38469871
[TBL] [Abstract][Full Text] [Related]
24. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
[TBL] [Abstract][Full Text] [Related]
25. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
26. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
Polyzos SA; Kang ES; Boutari C; Rhee EJ; Mantzoros CS
Metabolism; 2020 Oct; 111S():154203. PubMed ID: 32151660
[TBL] [Abstract][Full Text] [Related]
27. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.
Sanyal AJ; Friedman SL; McCullough AJ; Dimick-Santos L; ;
Hepatology; 2015 Apr; 61(4):1392-405. PubMed ID: 25557690
[TBL] [Abstract][Full Text] [Related]
28. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Ogawa Y; Yoneda M; Kobayashi T; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A
Expert Opin Pharmacother; 2019 Jan; 20(1):69-82. PubMed ID: 30411635
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of drugs for nonalcoholic steatohepatitis.
Shen B; Lu LG
J Dig Dis; 2021 Feb; 22(2):72-82. PubMed ID: 33385317
[TBL] [Abstract][Full Text] [Related]
30. Review article: new treatments in non-alcoholic fatty liver disease.
Townsend SA; Newsome PN
Aliment Pharmacol Ther; 2017 Sep; 46(5):494-507. PubMed ID: 28677333
[TBL] [Abstract][Full Text] [Related]
31. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery.
Cole BK; Feaver RE; Wamhoff BR; Dash A
Expert Opin Drug Discov; 2018 Feb; 13(2):193-205. PubMed ID: 29190166
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis.
Wong VW; Chitturi S; Wong GL; Yu J; Chan HL; Farrell GC
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):56-67. PubMed ID: 28404113
[TBL] [Abstract][Full Text] [Related]
33. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.
Chen MM; Cai JJ; Yu Y; She ZG; Li H
Gene Expr; 2019 Nov; 19(3):175-185. PubMed ID: 30940296
[TBL] [Abstract][Full Text] [Related]
34. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
[TBL] [Abstract][Full Text] [Related]
35. Emerging therapies for NASH - the future is now.
Geier A; Rau M
Expert Rev Clin Pharmacol; 2017 May; 10(5):467-469. PubMed ID: 28277800
[No Abstract] [Full Text] [Related]
36. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.
Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
Nutrients; 2014 Dec; 6(12):5583-99. PubMed ID: 25479248
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease from pathogenesis to management: an update.
Musso G; Gambino R; Cassader M
Obes Rev; 2010 Jun; 11(6):430-45. PubMed ID: 19845871
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Ahmed A; Wong RJ; Harrison SA
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
[TBL] [Abstract][Full Text] [Related]
39. The pharmacological management of NAFLD in children and adolescents.
Liyanagedera S; Williams RP; Veraldi S; Nobili V; Mann JP
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1225-1237. PubMed ID: 28803504
[TBL] [Abstract][Full Text] [Related]
40. Pharmacotherapy for NASH: Current and emerging.
Konerman MA; Jones JC; Harrison SA
J Hepatol; 2018 Feb; 68(2):362-375. PubMed ID: 29122694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
